Panelists discuss how the dose-response relationship is more pronounced with ipilimumab than with PD-1 inhibitors, explaining why toxicity increases with higher ipilimumab doses while efficacy may not proportionally improve with higher PD-1 inhibitor doses.
Dosing Considerations and Patient Selection
Key Discussion Points:
Key Points for Physicians:
Notable Insights:
For patients with brain metastases but significant comorbidities or frailty, clinicians may consider nivolumab/relatlimab based on emerging data from studies like Bluebonnet showing intracranial efficacy.
Clinical Significance:
Treatment selection requires careful patient stratification, weighing disease characteristics against patient factors, with dosing decisions that optimize the efficacy-toxicity balance for each individual patient.